Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Roger Douglas Weiss, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R21DA041682 (CHAN, KEVIN E) Mar 15, 2017 - Feb 28, 2019
    NIH
    Opioid Use and Abuse in the Dialysis Population
    Role: Co-Principal Investigator
  2. K24DA022288 (WEISS, ROGER D.) Apr 1, 2007 - Mar 1, 2019
    NIH
    Mentoring in drug abuse and dual diagnosis research
    Role: Principal Investigator
  3. UG1DA015831 (D'ONOFRIO, GAIL) Sep 30, 2002 - Feb 28, 2025
    NIH
    The National Drug Abuse Clinical Trials Network: New England Consortium Node
    Role: Co-Principal Investigator
  4. U10DA015831 (WEISS, ROGER D.) Sep 30, 2002 - Aug 31, 2015
    NIH
    The National Drug Abuse Treatment Clinical Trials Network (U10)
    Role: Co-Principal Investigator
  5. R01DA015968 (WEISS, ROGER D.) Sep 30, 2002 - Jan 31, 2009
    NIH
    Modifying Group Therapy for Bipolar Abusers
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kleinman RA, Weiss RD. Benzodiazepine-Involved Overdose Deaths in the USA: 2000-2019. J Gen Intern Med. 2022 Apr 12. PMID: 35415793.
    Citations:    Fields:    
  2. Weiner SG, Hendricks MA, El Ibrahimi S, Ritter GA, Hallvik SE, Hildebran C, Weiss RD, Boyer EW, Flores DP, Nelson LS, Kreiner PW, Fischer MA. Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone. PLoS One. 2022; 17(4):e0266561. PMID: 35381052.
    Citations:    Fields:    Translation:Humans
  3. Connery HS, Weiss RD, Griffin ML, Trinh CD, Kim J, Rockett IRH, McHugh RK. Suicidal motivations among opioid overdose survivors: Replication and extension. Drug Alcohol Depend. 2022 Jun 01; 235:109437. PMID: 35427980.
    Citations:    Fields:    Translation:Humans
  4. Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser YI, McHugh RK, McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE, Weiss RD, Wu LT. The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study. Addiction. 2022 Mar 16. PMID: 35293064.
    Citations:    Fields:    
  5. McHugh RK, Chase A, Trinh CD, Weiss RD. Are Pain and Negative Affect Coping Distinct Motives for Opioid Misuse? Subst Use Misuse. 2022; 57(6):848-852. PMID: 35258408.
    Citations:    Fields:    Translation:Humans
  6. Copersino ML, Slayter E, McHugh RK, Shedlack KJ, Lukas SE, Weiss RD. Clinical utility of a hybrid secondary and relapse prevention program in adults with mild intellectual disability or borderline intellectual functioning in community residential and day habilitation settings. Disabil Health J. 2022 Feb 26; 101293. PMID: 35337784.
    Citations:    Fields:    
  7. Weiner SG, El Ibrahimi S, Hendricks MA, Hallvik SE, Hildebran C, Fischer MA, Weiss RD, Boyer EW, Kreiner PW, Wright DA, Flores DP, Ritter GA. Factors Associated With Opioid Overdose After an Initial Opioid Prescription. JAMA Netw Open. 2022 01 04; 5(1):e2145691. PMID: 35089351.
    Citations: 1     Fields:    Translation:Humans
  8. McHugh RK, Hilton BT, Chase AM, Griffin ML, Weiss RD. Do people with opioid use disorder and posttraumatic stress disorder benefit from dding Individual opioid Drug Counseling to buprenorphine? Drug Alcohol Depend. 2021 11 01; 228:109084. PMID: 34607194.
    Citations:    Fields:    Translation:Humans
  9. Sugarman DE, Busch AB, McHugh RK, Bogunovic OJ, Trinh CD, Weiss RD, Greenfield SF. Patients' perceptions of telehealth services for outpatient treatment of substance use disorders during the COVID-19 pandemic. Am J Addict. 2021 09; 30(5):445-452. PMID: 34405475.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  10. Strain EC, Kampman KM, Weiss RD. Moving Beyond Medications That Act at the µ Receptor in the Treatment of Opioid Use Disorder. JAMA Psychiatry. 2021 07 01; 78(7):701-702. PMID: 33851964.
    Citations:    Fields:    Translation:Humans
  11. Hilton BT, Yusufov M, Rosellini AJ, Taghian NR, Weiss RD, Griffin ML, McHugh RK. Psychometric properties of the Anxiety Sensitivity Index-3 in adults with substance use disorders. J Subst Abuse Treat. 2022 01; 132:108507. PMID: 34214925.
    Citations:    Fields:    Translation:Humans
  12. Suzuki J, Weiss RD. Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence? J Addict Med. 2021 04 01; 15(2):91-92. PMID: 32909980.
    Citations: 1     Fields:    Translation:HumansAnimals
  13. Shulman M, Weiss R, Rotrosen J, Novo P, Costello E, Nunes EV. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)". Addict Sci Clin Pract. 2021 03 06; 16(1):15. PMID: 33676577.
    Citations: 3     Fields:    Translation:Humans
  14. Suzuki J, Johnson JA, Montgomery MW, Hayden MC, Price CN, Solomon DA, Liebschutz JM, Schnipper JL, Weiss RD. Medications for Opioid Use Disorder Demonstrate Clear Benefit for Patients With Invasive Infections: Letter-in-reply. J Addict Med. 2020 12; 14(6):518-519. PMID: 32187110.
    Citations:    Fields:    Translation:Humans
  15. Kneeland ET, Peckham AD, McHugh RK, Weiss RD, Beard C, Björgvinsson T. Tobacco Use Predicts Treatment Dropout and Outcome in an Acute, Transdiagnostic Psychiatric Treatment Setting. Behav Ther. 2021 07; 52(4):897-906. PMID: 34134829.
    Citations:    Fields:    Translation:Humans
  16. Becker WC, Krebs EE, Edmond SN, Lin LA, Sullivan MD, Weiss RD, Gordon AJ. A Research Agenda for Advancing Strategies to Improve Opioid Safety: Findings from a VHA State of the Art Conference. J Gen Intern Med. 2020 12; 35(Suppl 3):978-982. PMID: 33145681.
    Citations: 1     Fields:    Translation:Humans
  17. Taghian NR, McHugh RK, Griffin ML, Chase AR, Greenfield SF, Weiss RD. Associations between Childhood Abuse and Chronic Pain in Adults with Substance Use Disorders. Subst Use Misuse. 2021; 56(1):87-92. PMID: 33131372.
    Citations:    Fields:    Translation:Humans
  18. McHugh RK, Trinh CD, Griffin ML, Weiss RD. Validation of the craving scale in a large sample of adults with substance use disorders. Addict Behav. 2021 02; 113:106651. PMID: 33086155.
    Citations:    Fields:    Translation:Humans
  19. Lipsitz SR, Fitzmaurice GM, Weiss RD. Using Multiple Imputation with GEE with Non-monotone Missing Longitudinal Binary Outcomes. Psychometrika. 2020 12; 85(4):890-904. PMID: 33006740.
    Citations:    Fields:    Translation:Humans
  20. Kimmel SD, Walley AY, Li Y, Linas BP, Lodi S, Bernson D, Weiss RD, Samet JH, Larochelle MR. Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis. JAMA Netw Open. 2020 10 01; 3(10):e2016228. PMID: 33052402.
    Citations: 16     Fields:    Translation:Humans
  21. Weiss RD. Establishing the First Annual Meetings of the American Academy of Addiction Psychiatry. Am J Addict. 2020 09; 29(5):373-374. PMID: 32902043.
    Citations:    Fields:    Translation:Humans
  22. McHugh RK, Geyer RB, Chase AR, Griffin ML, Bogunovic O, Weiss RD. Sex differences in benzodiazepine misuse among adults with substance use disorders. Addict Behav. 2021 01; 112:106608. PMID: 32861991.
    Citations: 5     Fields:    Translation:Humans
  23. Suzuki J, Johnson JA, Montgomery MW, Hayden MC, Price CN, Solomon DA, Liebschutz JM, Schnipper JL, Weiss RD. Long-term Outcomes of Injection Drug-related Infective Endocarditis Among People Who Inject Drugs. J Addict Med. 2020 Jul/Aug; 14(4):282-286. PMID: 31634202.
    Citations: 7     Fields:    Translation:Humans
  24. McHugh RK, Votaw VR, Taghian NR, Griffin ML, Weiss RD. Benzodiazepine misuse in adults with alcohol use disorder: Prevalence, motives and patterns of use. J Subst Abuse Treat. 2020 10; 117:108061. PMID: 32811622.
    Citations: 2     Fields:    Translation:Humans
  25. King CD, Hilton BT, Greenfield SF, McHugh RK, Griffin ML, Weiss RD, Ressler KJ. Anxiety sensitivity and grit as mediators between childhood abuse and relapse risk for substance use. Child Abuse Negl. 2020 09; 107:104568. PMID: 32559552.
    Citations:    Fields:    Translation:Humans
  26. Votaw VR, Witkiewitz K, Vowles KE, Weiss RD, Griffin ML, McHugh RK. Pain interference and catastrophizing are not associated with polysubstance use among treatment-seeking patients with substance use disorders and chronic pain. Am J Drug Alcohol Abuse. 2020 09 02; 46(5):604-612. PMID: 32529847.
    Citations: 1     Fields:    Translation:Humans
  27. Peckham AD, Griffin ML, McHugh RK, Weiss RD. Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder. Drug Alcohol Depend. 2020 Jun 12; 213:108122. PMID: 32563846.
    Citations: 4     Fields:    
  28. Loflin MJE, Kiluk BD, Huestis MA, Aklin WM, Budney AJ, Carroll KM, D'Souza DC, Dworkin RH, Gray KM, Hasin DS, Lee DC, Le Foll B, Levin FR, Lile JA, Mason BJ, McRae-Clark AL, Montoya I, Peters EN, Ramey T, Turk DC, Vandrey R, Weiss RD, Strain EC. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug Alcohol Depend. 2020 07 01; 212:107993. PMID: 32360455.
    Citations: 13     Fields:    Translation:Humans
  29. McHugh RK, Janes AC, Griffin ML, Taghian N, Greenfield SF, Weiss RD. Clinical Correlates of Smoking Status in Men and Women with Opioid Use Disorder. Subst Use Misuse. 2020; 55(7):1054-1058. PMID: 32037945.
    Citations: 1     Fields:    Translation:Humans
  30. Connery HS, Weiss RD. Discontinuing Buprenorphine Treatment of Opioid Use Disorder: What Do We (Not) Know? Am J Psychiatry. 2020 02 01; 177(2):104-106. PMID: 32008394.
    Citations: 2     Fields:    Translation:Humans